Havax is a combination medication containing Artemether and Lumefantrine used to treat acute uncomplicated malaria.
Artemether and Lumefantrine interfere with the malaria parasite's heme conversion process and inhibit nucleic acid and protein synthesis.
Orally with fatty food or drinks twice daily for three days. Dosage is based on body weight.
Hypersensitivity to ingredients, severe malaria, certain drug interactions (CYP2D6 substrates, QTc prolonging drugs, strong CYP3A4 inducers).
QTc prolonging drugs, CYP2D6 substrates, strong CYP3A4 inducers, hormonal contraceptives, quinine, mefloquine.
Headache, dizziness, decreased appetite, palpitations, vomiting, abdominal pain, nausea, joint pain, and fatigue.
Symptomatic and supportive therapy, including ECG and blood potassium monitoring.
Artemether is rapidly absorbed and metabolized. Lumefantrine's absorption is slower and has a longer half-life. Food enhances absorption of both.
Not recommended, especially during the first trimester of pregnancy or while breastfeeding.
Below 30°C, protected from light and moisture, and out of reach of children.